A cohort of 253 isolated LR resections from 3211 primary STS resections enabled evaluation of post-recurrence prognosticators with median 5.3-year follow-up and 83 disease-specific deaths. Higher LR ...
Investigators explored the utility of unplanned resections, also called reresection, among patients who have soft tissue sarcomas. Experts have issued caution when considering reresection among ...
Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the extremity, a randomized trial showed. In patients with mostly undifferentiated ...
Does combined dose intensification radiotherapy improve disease control in resectable retroperitoneal sarcoma? Long-term results of a phase I/II trial. This is an ASCO Meeting Abstract from the 2012 ...
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results ...
Efficacy and Tolerability of a Low-Dose Continuous Regimen of Regorafenib in Refractory Synovial Sarcomas: A Single-Arm, Phase II Trial From India Diagnostic concordance was observed in 296 cases ...
Patients with soft tissue sarcomas showed improved functional results, quality of life and fewer side effects when treated with RT-therapy. Among patients with soft tissue sarcomas (STS), study ...
Patients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely receive hypofractionated treatment over three weeks instead of five, with comparable tumor ...
Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients with soft tissue sarcoma Over three-fold increase in tumour ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — A novel T-cell receptor therapy showed promising antitumor activity in patients with advanced soft ...
For the first time, a product is available specifically for use in patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors. The product is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results